Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (13)
  • Open Access

    REVIEW

    Current innovations in head and neck cancer: From diagnostics to therapeutics

    TAYYABA SATTAR1, IQRA NAZIR1, MEHREEN JABBAR1, JAVARIA MALIK1, SABA AFZAL1, SANA HANIF2, SEYED ALI MOSADDAD3, AHMED HUSSAIN4,*, HAMID TEBYANIYAN2,*

    Oncology Research, Vol.33, No.5, pp. 1019-1032, 2025, DOI:10.32604/or.2025.060601 - 18 April 2025

    Abstract Background: Head and neck cancers (HNC) account for a significant global health burden, with increasing incidence rates and complex treatment requirements. Traditional diagnostic and therapeutic approaches, while effective, often result in substantial morbidity and limitations in personalized care. This review provides a comprehensive overview of the latest innovations in diagnostics and therapeutic strategies for HNC from 2015 to 2024. Methods: A review of literature focused on pe-reviewed journals, clinical trial databases, and oncology conference proceedings. Key areas include molecular diagnostics, imaging technologies, minimally invasive surgeries, and innovative therapeutic strategies. Results: Technologies like liquid biopsy next-generation sequencing… More >

  • Open Access

    REVIEW

    Targeting cell cycle regulators: A new paradigm in cancer therapeutics

    GARIMA SINGH#, SONIKA KUMARI SHARMA#, NEELU MISHRA, AASTHA SONI, MANSHI KUMARI, SAMARENDRA KUMAR SINGH*

    BIOCELL, Vol.48, No.12, pp. 1639-1666, 2024, DOI:10.32604/biocell.2024.056503 - 30 December 2024

    Abstract Dysregulation of the cell cycle is a molecular hallmark of cancer, which leads to uncontrolled proliferation and self-renewal of neoplastic cells. To maintain this phenotype, cells acquire multiple molecular alterations and bypass several cellular checkpoints that are involved in the prevention of genomic instability and uncontrolled cell proliferation. Therefore, targeting cell cycle regulators could prove to be a promising anti-cancer approach. Recent advancements in the understanding of cancer cell susceptibilities have revealed a therapeutic opportunity to selectively target the cell cycle in malignant cells. This review highlights major cell cycle dysregulation in cancerous cells and More > Graphic Abstract

    Targeting cell cycle regulators: A new paradigm in cancer therapeutics

  • Open Access

    REVIEW

    The roles and mechanisms of miRNA in HBV-HCC carcinogenesis: Why no therapeutic agents after 30 years?

    KURT SARTORIUS1,2,3,*, BENN SARTORIUS4, CHERIE WINKLER5, ANIL CHUTURGOON2, ANNA KRAMVIS1, PING AN5, WEIGANG ZHANG6, YUNJIE LU3,6,7,*

    BIOCELL, Vol.48, No.11, pp. 1543-1567, 2024, DOI:10.32604/biocell.2024.055505 - 07 November 2024

    Abstract Hepatitis B-associated hepatocellular carcinoma (HBV-HCC) remains an intractable high-mortality solid tumor cancer that accounted for 42% of global HCC cases in 2019. Despite some developments in systemic therapy, only a small subset of late-stage HCC patients responds positively to recently developed therapeutic innovations. MicroRNAs (miRNAs) act as an ancillary epigenetic system that can regulate genome expression in all cancer pathways including HCC. The molecular mechanisms of miRNA regulation in cancer pathogenesis offered researchers a new approach that was widely hoped would translate into miRNA-based drugs and diagnostics. Thirty years on, miRNA-based diagnostic and therapeutic agents… More >

  • Open Access

    REVIEW

    Modulatory role of plant-derived metabolites on host-microbiota interactions: personalized therapeutics outlook

    POOJA YADAV, NAR SINGH CHAUHAN*

    BIOCELL, Vol.48, No.8, pp. 1127-1143, 2024, DOI:10.32604/biocell.2024.051318 - 02 August 2024

    Abstract A diverse array of microbes in and on the human body constitute the microbiota. These micro-residents continuously interact with the human host through the language of metabolites to dictate the host’s physiology in health and illnesses. Any biotic and abiotic component ensuring a balanced host-microbiota interaction are potential microbiome therapeutic agents to overcome human diseases. Plant metabolites are continually being used to treat various illnesses. These metabolites target the host’s metabolic machinery and host-gut microbiota interactions to overcome human diseases. Despite the paramount therapeutic significance of the factors affecting host-microbiota interactions, a comprehensive overview of More > Graphic Abstract

    Modulatory role of plant-derived metabolites on host-microbiota interactions: personalized therapeutics outlook

  • Open Access

    ARTICLE

    Dual ligand-targeted Pluronic P123 polymeric micelles enhance the therapeutic effect of breast cancer with bone metastases

    HUAN GAO1,2, JIE ZHANG1, TONY G. KLEIJN1,3,4, ZHAOYONG WU5, BING LIU1,6, YUJIN MA6, BAOYUE DING1,*, DONGFENG YIN2,*

    Oncology Research, Vol.32, No.4, pp. 769-784, 2024, DOI:10.32604/or.2023.044276 - 20 March 2024

    Abstract Bone metastasis secondary to breast cancer negatively impacts patient quality of life and survival. The treatment of bone metastases is challenging since many anticancer drugs are not effectively delivered to the bone to exert a therapeutic effect. To improve the treatment efficacy, we developed Pluronic P123 (P123)-based polymeric micelles dually decorated with alendronate (ALN) and cancer-specific phage protein DMPGTVLP (DP-8) for targeted drug delivery to breast cancer bone metastases. Doxorubicin (DOX) was selected as the anticancer drug and was encapsulated into the hydrophobic core of the micelles with a high drug loading capacity (3.44%). The… More > Graphic Abstract

    Dual ligand-targeted Pluronic P123 polymeric micelles enhance the therapeutic effect of breast cancer with bone metastases

  • Open Access

    REVIEW

    Biological, pathological, and multifaceted therapeutic functions of exosomes to target cancer

    VIGNESH BALAJI E1, DIVYA RAMESH2, MANISHA CHUNGAN SHAJU3, AKSHARA KUMAR4, SAMYAK PANDEY1, RAKSHA NAYAK1, V. ALKA5, SRISHTI MUNJAL6, AMIR SALIMI7, K. SREEDHARA RANGANATH PAI1,*, SHANKAR M. BAKKANNAVAR2

    Oncology Research, Vol.32, No.1, pp. 73-94, 2024, DOI:10.32604/or.2023.030401 - 15 November 2023

    Abstract Exosomes, small tiny vesicle contains a large number of intracellular particles that employ to cause various diseases and prevent several pathological events as well in the human body. It is considered a “double-edged sword”, and depending on its biological source, the action of exosomes varies under physiological conditions. Also, the isolation and characterization of the exosomes should be performed accurately and the methodology also will vary depending on the exosome source. Moreover, the uptake of exosomes from the recipients’ cells is a vital and initial step for all the physiological actions. There are different mechanisms More > Graphic Abstract

    Biological, pathological, and multifaceted therapeutic functions of exosomes to target cancer

  • Open Access

    REVIEW

    Protein-mediated interactions in the dynamic regulation of acute inflammation

    RYAN STARK*

    BIOCELL, Vol.47, No.6, pp. 1191-1198, 2023, DOI:10.32604/biocell.2023.027838 - 19 May 2023

    Abstract Protein-mediated interactions are the fundamental mechanism through which cells regulate health and disease. These interactions require physical contact between proteins and their respective targets of interest. These targets include not only other proteins but also nucleic acids and other important molecules as well. These proteins are often involved in multibody complexes that work dynamically to regulate cellular health and function. Various techniques have been adapted to study these important interactions, such as affinity-based assays, mass spectrometry, and fluorescent detection. The application of these techniques has led to a greater understanding of how protein interactions are More >

  • Open Access

    REVIEW

    Role of necroptosis in spinal cord injury and its therapeutic implications

    JIAWEI FU1,2,3,#, CHUNSHUAI WU1,2,3,#, GUANHUA XU1,2,3, JINLONG ZHANG1, YIQIU LI1, CHUNYAN JI1,2,3, ZHIMING CUI1,2,3,*

    BIOCELL, Vol.47, No.4, pp. 739-749, 2023, DOI:10.32604/biocell.2023.026881 - 08 March 2023

    Abstract Spinal cord injury (SCI), a complex neurological disorder, triggers a series of devastating neuropathological events such as ischemia, oxidative stress, inflammatory events, neuronal apoptosis, and motor dysfunction. However, the classical necrosome, which consists of receptor-interacting protein (RIP)1, RIP3, and mixed-lineage kinase domain-like protein, is believed to control a novel type of programmed cell death called necroptosis, through tumour necrosis factor-alpha/tumour necrosis factor receptor-1 signalling or other stimuli. Several studies reported that necroptosis plays an important role in neural cell damage, release of intracellular pro-inflammatory factors, lysosomal dysfunction and endoplasmic reticulum stress. Recent research indicates that More >

  • Open Access

    ARTICLE

    Pharmacotherapeutics and molecular docking studies of alpha-synuclein modulators as promising therapeutics for Parkinson’s disease

    RAHAT ALI1, AFTAB ALAM2, SATYENDRA K. RAJPUT3, RAZI AHMAD4,*

    BIOCELL, Vol.46, No.12, pp. 2681-2694, 2022, DOI:10.32604/biocell.2022.021224 - 10 August 2022

    Abstract Parkinson’s disease (PD) is an age-related neurodegenerative ailment that affects dopamine-producing neurons in a specific area of the brain called the substantia nigra of the ventral midbrain. It is clinically characterized by movement disorder and marked with unusual synaptic protein alpha-synuclein accumulation in the brain. To date, only a few Food and Drug Administration (FDA) approved drugs are available on the market for the treatment of PD. Nonetheless, these drugs show parasympathomimetic related adverse events and remarkably higher toxicity; hence, it is important to find more efficacious molecules to treat PD. In our study, We… More >

  • Open Access

    VIEWPOINT

    Prognostic, diagnostic and therapeutic potential of endothelial progenitor cells for patients with ischaemic stroke: Hype or Hope

    ULVI BAYRAKTUTAN*

    BIOCELL, Vol.46, No.7, pp. 1593-1598, 2022, DOI:10.32604/biocell.2022.018679 - 17 March 2022

    Abstract Ischaemic stroke is a debilitating disease with immense personal, societal and economic impact. Thrombolysis with recombinant tissue plasminogen activator remains the only approved pharmacotherapy for this disease. As each year less than 1% of eligible patients receive this therapy worldwide, efficacious new therapeutics are desperately needed. Emerging evidence suggest endothelial progenitor cells (EPCs), capable of repairing damaged vasculature, as one such therapeutics. However, questions regarding their optimal dose, delivery route and in vivo survivability remain largely unanswered. Outgrowth endothelial cells, generated in large numbers by ex vivo expansion of EPCs, enable effective assessment of these More >

Displaying 1-10 on page 1 of 13. Per Page